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Aim: Albendazole (ABZ) is a broad-spectrum antiparasitic agent with poor aqueous solubility, which leads
to poor/erratic bioavailability and therapeutic failures. Here, we aimed to produce a novel formulation
of ABZ nanocrystals (ABZNC) and assess its pharmacokinetic performance in mice. Results/methodology:
ABZNC were prepared by high-pressure homogenization and spray-drying processes. Redispersion capac-
ity and solid yield were measured in order to obtain an optimized product. The final particle size was
415.69±7.40 nm and the solid yield was 72.32%. The pharmacokinetic parameters obtained in a mice
model for ABZNC were enhanced (p < 0.05) with respect to the control formulation. Conclusion: ABZNC
with improved pharmacokinetic behavior were produced by a simple, inexpensive and potentially scalable
methodology.
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The design and production of drug nanocrystals (NC) has been treated as the ultimate universal formulation
strategy of drugs with poor solubility and high permeability [1]. NC by definition are carrier-free nanoparticulate
systems composed of 100% drug, being generally stabilized by surfactants or polymeric steric agents; according to the
definition of nanoparticles, the mean particle size is below 1μm [2]. NC are generally produced as aqueous dispersions
(nanosuspensions), which usually need further solvent removal in order to obtain redispersible powders [3]. NC
display a series of benefits in the oral administration of poorly soluble drugs, including improved absorption, higher
bioavailability, rapid action onset, reduced fed/fasted state and intersubject variability [4]. The outstanding features
of NC have caught the attention of the industry and a total of six products have been launched on the market [5].
Albendazole (ABZ) is a methyl carbamate benzimidazole (BZD) antiparasitic agent with a broad-spectrum
activity that acts by preventing tubulin aggregation [6]. The high efficacy of ABZ is compromised by its extremely
low aqueous solubility, which has been related to a poor/erratic bioavailability and therapeutic failures [7]. ABZ is
a class II drug in the Biopharmaceutic Classification System [8], which means it exhibits low solubility and high
permeability. For class II drugs, an improvement in solubility might result in increased drug absorption.
To address this, multiple approaches have been aimed at improving ABZ water solubility and dissolution rates,
such as the preparation of chitosan-microspheres [9], oil/water emulsion [10], microcrystals [11], solid dispersions [12],
incorporation into liposomes [13], complexation with cyclodextrins [14], co-grinding [15] and more recently, several
nanoparticulate formulations [16–19]. Moreover, multiple authors have demonstrated that the enhanced bioavailabil-
ity of the parent drug/active metabolite is correlated with an improved in vitro–in vivo efficacy [7,9–11,13,14,16–19].
Nevertheless, most of the strategies described above have shown limited capacity in the improvement of ABZ
bioavailability/efficacy, and the development of free-organic solvent, inexpensive, highly reproducible and indus-
trially feasible approaches is needed.
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We have recently reported a methodology for the preparation of an ABZ nano-sized redispersible powder
(ABZNC) by the combination of high-pressure homogenization (HPH) and spray drying (SD), besides we per-
formed the in vitro characterization of the obtained materials [20]. Nevertheless, an optimization of this process
and the pharmacokinetic (PK) performance of the ABZNC remained unexplored. Then, the aim of this work
was to study the influence of different parameters involved in the ABZNC production technique and to assay the
pharmacokinetic performance of this novel formulation in mice.
Materials & methodology
Chemicals
ABZ pharmaceutical grade was purchased from Todo Droga R©, Córdoba, Argentina and Poloxamer 188 (P188)
was provided from Rumapel, a representative of BASF R© in Argentina. All other reagents used in this work were of
proanalysis quality, and ultrapure water (HF-Super Easy Series, Heal Force, Shanghai, China) was used in all assays.
Production of ABZ nanosuspensions
ABZ nanosuspensions were prepared as follows: 2.5 g of ABZ and 1.25 or 2.5 g of P188 (Suspension 1 [S1] and
Suspension 2 [S2], respectively] were accurately weighed and ground in a mortar; deionized water was gradually
added until 100 g of a homogeneous suspension was obtained. Afterwards, the samples were transferred to a beaker
and sonicated for 5 min. A premilling process of three cycles at 500 bar and 30 cycles of HPH at 1200 bar (Avestin
C5 Emulsiflex R©, Ottawa, Ontario, Canada) was applied. The temperature was kept at 10◦C using a heat exchanger
provided by the homogenizer manufacturer.
Nanocrystals production by spray-drying
S1 and S2 were dried on a laboratory-scale Mini Spray-dryer Büchi B-290 (Büchi Labortechnik AG, Flawil,
Switzerland) equipped with a dehumidifier module. A two-fluid nozzle with a cap orifice diameter of 0.5 mm was
used, and the operating conditions were: atomization air (l/h): 819, aspiration: 75%, temperature (◦C): 45 and
pump: 5%. S1 was also dried with the addition of 1.25 g of the supporting agents, anhydrous lactose (L) and
colloidal silicon dioxide (CSD), 10 min before drying, under magnetic stirring. Different L-CSD percent ratios
were used in this experiment, namely 100–0, 75–25, 60–40 and 50–50. In order to maintain sample homogeneity,
slow magnetic stirring was kept constant during the drying process. The powders obtained by SD were evaluated
by measuring particle size, polydispersity index (PDI), solid yield (SY) and moisture content (MC). The recovered
SY was calculated as the ratio of the powder weight collected after each drying experiment (Wf, dry basis) and the





x 100 (Equation 1)
Particle size & PDI
The particle size and PDI values of the ABZNC were determined by Photon Correlation Spectroscopy (DelsaTM
Nano C Particle Analyzer, Beckman and Coulter, Inc., Brea, CA, USA). Before taking measurements, samples were
diluted with ultrapure water in order to obtain the required absorption intensity. For this purpose, 10 mg of powder
were added to 5 ml of water, and the resultant suspension was shaken by hand during 1 min before carrying out
the assays.
Moisture content
The powder MC was measured immediately after the SD step in a moisture analyzer with halogen heating (OHAUS
M45 R©, OHAUS, Greifensee, Switzerland).
Dissolution study
50 mg of pure ABZ and the equivalent amount of the active in a physical mixture (PM) and ABZNC were placed in
transparent gelatin capsules and assayed using a USP XXIV dissolution apparatus 1 (Sotax AT 7 Smart, Sotax, MA,
USA) at 37 ± 0.5◦C. The dissolution media was HCl 0.1 M (900 ml) and the basket speed was set at 75 rpm. 5 ml
samples were taken at predetermined time intervals over 2 h with reposition of fresh medium. The concentrations of
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Figure 1. Particle size and polydispersity index (PI) reduction of S1 and S2 containing albendazole and P188 at
different ratios (1:0.5 and 1:1 respectively). Processed by high-pressure homogenization at 30 cycles at 1200 bar.
dissolved ABZ in the aliquots were determined using a UV–Vis spectrophotometer (Evolution R© 300, Thermofisher
Scientific, MA, USA) at 297 nm. The dissolution rates of all samples were measured in triplicate.
Physical mixture
For the dissolution and pharmacokinetic studies, a PM was used as a control. This was prepared in an agate mortar
by grounding softly ABZ and P188 powders in a 1:1 ratio for 10 min.
Pharmacokinetic assay
The PK study was performed in male Balb/c mice. The animals were housed in a temperature controlled (21 ± 2◦C),
light-cycle (12 h light/dark cycle) room with food and water provided ad libitum. 112 healthy mice were allocated
into two groups of 56 animals and treated with ABZNC and the control (PM), respectively. Both treatments were
suspended in ultrapure water and manually shaken before each administration. A single dose of ABZ 25 mg/kg was
administered using an intragastric cannula and four mice (n = 4) were used for each of the assayed times. Blood
samples were collected in heparinized plastic tubes at time 0 (pretreatment) and in the following post-treatment
times: 0.08, 0.25, 0.5, 0.75, 1, 2, 3, 4, 6, 8, 10, 12, 15 and 24 h. Blood samples were centrifuged at 2000 × g and
4◦C for 15 min and the recovered plasma was stored at -20◦C until analysis by HPLC.
Analysis of the ABZ sulfoxide metabolite in plasma
The quantification of ABZ and its sulfoxide metabolite isolated from plasma was performed by an HPLC method-
ology described in a previous work [12,21]. The concentration versus time curve for the metabolite ABZSO in
plasma for each animal group after the different treatments was fitted using PK Solution 2.0 (Summit research
services, OH, USA). The peak concentration (Cmax) and time to peak concentration were obtained from the plotted
concentration–time curve of each analyte. The area under the concentration–time curve was calculated by the linear
trapezoidal rule [22].
Statistics
In the PK study, a nonparametric Mann–Whitney test was used for the multiple statistical comparisons of the data
obtained from the different animal groups. These statistical analyses were performed using the InfoStat software [23],
considering a p-value < 0.05 as significant.
Results & discussion
Figure 1 shows the particle size and PDI variation during the HPH of S1 and S2 containing different ABZ:P188
ratios (1:0.5 and 1:1 respectively). When the homogenization pressure is raised to 1200 bar, a few amount of cycles
was enough to achieve the submicron range, that is, at five cycles, the particle size was 935.69 ± 152.10 nm for
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Table 1. Particle size and polydispersity index of nanosuspensions S1, S2 and its redispersed powdered forms PS1 and PS2.
The spray-drying solid yield and moisture content of PS1 and PS2 are also shown.
Sample Particle size (nm) PDI SY (%) MC (%)
S1 420.23 ± 10.14 0.274 ± 0.007 – –
PS1 550.16 ± 8.94 0.230 ± 0.020 10 2.35
S2 372.43 ± 5.19 0.256 ± 0.005 – –
PS2 415.69 ± 7.40 0.245 ± 0.006 72.32 3.18
MC: Moisture content; PDI: Polydispersity index; PS1: Powder from suspension 1; PS1: Powder from suspension 2; S1: Suspension 1; S2: Suspension 2; SY: Solid yield.
S1 and 820.43 ± 89.52 nm for S2 with a minimum at 30 cycles of 420.43 ± 10.14 nm and 372.43 ± 5.19,
respectively. The PDI was also improved during the process with a value of 0.274 ± 0.007 (S1) and 0.256 ± 0.005
(S2) at 30 cycles. In both cases, the particle size diminution is bigger during the first 10–15 cycles while a decrease
in nanonization rate is observed after 20 cycles, probably because of the exhaustion of weak points in the drug
particle [2].
After HPH, the nanosuspensions were spray dried and the PY, MC and redispersion capacity were measured.
The obtained powders from S1 and S2 (PS1 and PS2, respectively) presented low MC values (2.35 and 3.18%,
respectively) and this was related to the conditions used in the SD experiments. A high atomization air pressure
(819 l/h) and low feed rate (pump: 5%) allowed the generation of very fine droplets and consequently, a large
specific surface when the suspension was sprayed in the drying chamber, thus permitting an efficient loss of water.
On the other hand, a high redispersion capacity was observed since the particle size and PDI of PS1 and PS2
were similar to the correspondent original suspensions (see Table 1); this was attributed to the presence of P188
soluble links between the drug particles, whose dissolution allowed the formation of nano-sized ABZ dispersions
upon contact with water. The concentration of P188 also influenced the recovery of solids in the collector as an
augmented proportion of this polymer in the suspension produced a sharp increase in SY. This was related to the
increased amount of solids in the sprayed droplet, which produced an augmented density of the particles, thus
facilitating its separation in the cyclone.
With the aim of improving the SY of S1 and maintaining its redispersion capacity, 1.25 g of carrier materials L
and CSD were added to the suspension at different ratios. As shown in Figure 2, when the amount of L was 100%,
the sample presented enough redispersion performance with a particle size of 453.1 nm, but on the other hand, the
SY was poorly increased (21.28%). Otherwise, samples containing lower L-CSD ratios produced greater SY, that
is, 75–25: 47.96%; 60–40: 53.52% and 50–50: 67.52%. CSD is a highly porous material, which permits a rapid
water removal, increasing the drying efficiency. Nevertheless, this improvement tendency in the SY was detrimental
to the ability of redispersion since the powdered material particle sizes increased, that is, L-CSD 60–40: 641.03 nm
and L-CSD 50–50: 919.20 nm. Based on the observed results, and considering the high PY and redispersion
capacity of PS2, composition of which was ABZ and P188 at a ratio of 1:1, it was chosen for further investigation.
Since low aqueous solubility of ABZ may limit its absorption during GI transit, the study of its dissolution rate
in the stomach is thought to be pivotal. Thus, the biopharmaceutic behavior of the nano-sized formulation was
assayed simulating the acidic conditions of the stomach (HCl 0.1 M).
In the dissolution assay (Figure 3), PS2 presented high dissolution rate (Q1h: 74.43%), while PM and the pure
ABZ did not exceed 10% at 1 h (Q1h: 7.77% and Q1h: 3.7%, respectively). In agreement with the Noyes–Whitney,
and Ostwald–Freundlich equations, a decrease in particle size led to an increase in the specific contact surface,
enhancing the drug dissolution velocity and saturation solubility [24].
Poloxamers are polyoxyethylene–polyoxypropylene block copolymer nonionic surfactants that have been widely
used as wetting and solubilizing agents. The polyoxyethylene segment is hydrophilic whereas the polyoxypropylene
segment is hydrophobic. The high percentage of P188 in the formulation (50% w/w) permits the formation of
the previously described water-soluble links, thus resulting in a complete redispersion of the powdered material,
which was visually confirmed as the dissolution vessels were completely opalescent after the disintegration of the
transparent gelatine capsules within 10 min of the test. It is important to note that P188 has the disadvantage of
forming in situ thermosensitive gels that might delay the drug release from the formulation, as reported by Dib et
al. [25]. Nevertheless, according to this study, this behavior seemed not to affect drug dissolution from the gelatin
capsules. Regarding the potential surfactant effect of P188 in the dissolution rate of ABZ it is negligible, which can
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Figure 2. Re-dispersion particle size and spray-drying
solid yield of S1 added with L and colloidal silicon

























Figure 3. Dissolution profile of albendazole
nanocrystals (PS2). Physical mixture and pure
albendazole in 900 ml of HCl 0.1 N, apparatus 2, 75 rpm
at 37◦C.
ABZNC: ABZ nanocrystal.
be confirmed analyzing Figure 3 where pure ABZ and the PM (containing 50% of P188) presented very similar
dissolution profiles.
On the other hand, amorphization of ABZ during the formulation could lead to an increased dissolution rate,
nevertheless, we have previously demonstrated that the crystalline state of the pure ABZ drug remains unchanged
in the ABZNC [20].
However, the higher dissolution rate observed for the ABZNC does not necessarily guarantee an improvement
in pharmacokinetic parameters, making further in vivo studies necessary.
Pharmacokinetics
When administered orally, ABZ is extensively metabolized to an active sulfoxide metabolite (ABZSO) in the liver,
and further oxidation leads to the second inactive metabolite, ABZ sulfone [26]. To achieve a suitable plasma
concentration of the ABZSO, ABZ (a weak base) must dissolve in the acid environment of the stomach to
finally permeate the duodenal membrane by a passive diffusion process which is independent of the administered
dose [6]. NC of basic drugs are more easily affected by pH variation in the GI tract. For weak bases, a nano-
sized drug formulation will dissolve fast and more efficiently in the low stomach pH environment, but in the
future science group www.futuremedicine.com 93





































Figure 4. Pharmacokinetic profile of ABZNC and PM in
mice after asingle intragastric administration of
albendazole (ABZ; 25 mg/kg).
ABZNC: ABZ nanocrystal; ABZSO: Albendazole sulfoxide.
Table 2. Pharmacokinetic parameters of the sulfoxide metabolite (albendazole extensively metabolized to active
sulfoxide metabolite) after a single oral administration of albendazole nanocrystals and control formulation at
25 mg/kg.
Tmax (h) Cmax (μg/ml) AUC0→∞ (μg.h/ml)
ABZNC 0.31 ± 0.13† 4.76 ± 0.17† 19.70 ± 0.45†
Control (PM) 1.25 ± 0.87 2.14 ± 0.12 10.71 ± 0.90
Data are expressed as mean ± SD (n = 6).
†
p  0.05 vs control.
ABZNC: Albendazole nanocrystal; ABZSO: Albendazole sulfoxide; AUC0→∞: Area under the plasma concentration–time curve up to time infinity; Cmax: Peak plasma concentration; Tmax:
Time to reach peak plasma concentration.
transit to duodenum the rise in pH may illicit uncontrolled precipitation of drug substance [27]. Nonetheless, this
phenomenon seemed not to affect our formulation since its pharmacokinetic performance was truly increased.
Although the GI transit in mice is rapid, we hypothesized that the gastric emptying is gradual, thus permitting
the absorption of the active before achieving its saturation concentration in the duodene and its consequent
precipitation.
It has been reported that the pharmacokinetic profiles of BZD anthelmintics may differ depending on the animal
species. The difference in the anatomic features could influence the passage of digesta through the GI tract and
hence, affect the pharmacokinetic performance of such molecules [12].
Figure 4 shows the pharmacokinetic profiles of ABZSO after a single oral administration of ABZNC and the
control formulation at 25 mg/kg. ABZ was not detected in the plasma, whereas ABZSO was detected in both
treatments up to 15 h. ABZNC produced a rapid increase in the sulfoxide plasma concentration, achieving a
maximum at 0.31 ± 0.13 h, while the control presented the Cmax at 1.25 ± 0.87 h. The area under the plasma
concentration–time curve up to time infinity value for ABZNC (19.70 ± 0.45 μg.h/ml) was almost twice that
obtained for the control group (10.71 ± 0.90 μg.h/ml). The Cmax value observed for ABZNC was 1.2-fold
higher (p < 0.05) than the control (4.76 ± 0.17 μg/ml and 2.14 ± 0.12 μg/ml, respectively) (see Table 2). This
augmented plasma exposure of ABZSO could lead to an improvement in the treatment of echinococcosis (hydatid
cyst) in agreement with the results previously obtained by our group when ABZ prepared as solid dispersions was
administered in a murine model [7]. Moreover, the potential of ABZ to induce an antitumor effect by inducing
oxidative cleavage on DNA has been recently discussed [28]; in this sense, the results here exposed could have a
tremendous impact on public health.
As shown in Figure 5, an optimized NC formulation produced by the combination of HPH and SD must have
a suitable balance between the feasibility of the drying process (i.e., SY), the redispersion capacity of the obtained
powdered material (particle size and PDI) and the final drug percentage formula (drug loading). Here, we were
able to obtain ABZNC through a potentially scalable and inexpensive process. This material was also capable of
magnify ABZ absorption in the GI tract.
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Figure 5. An optimized formulation of ABZNC must balance a high re-dispersion and solid yield maintaining a high
drug-loading capacity. The enlarged specific surface enables an increased in the dissolution rate, saturation
concentration and mucoadhesivity, leading to enhanced albendazole plasma exposure.
ABZNC: ABZ nanocrystal.
Conclusion
ABZNCs were obtained by means of a combined process of premilling (three cycles at 500 bar) and HPH (30 cycles
at 1200 bar). Then, using an optimized SD process, this dispersion was transformed into a highly redispersible
powder able to be incorporated into solid pharmaceutical dosage forms (tablet, capsule). ABZNC were capable of
increase the oral absorption of the drug in a murine model.
Future perspective
Based on the promising outcomes of the pharmacokinetic assay, it would be propitious to move forward with
further in vivo efficacy studies aimed at evaluation of the potential of ABZNC in the treatment of hydatid cyst
in humans or ancylostomiasis, a zoonotic parasitic disease that is highly prevalent in dogs. On the other hand,
regarding the potential of ABZ as an antitumor agent, an increase in the bioavailability could be very beneficial.
Moreover, the flexibility of the processes involved here could permit the formulation of other antiparasitic BZD
drugs with poor aqueous solubility such as fenbendazole or flubendazole.
Executive summary
 Albendazole (ABZ) is a broad-spectrum antiparasitic agent used in human and veterinary medicine with a poor
aqueous solubility.
• ABZ acts by preventing tubulin aggregation of eukaryotic cells.
• The low solubility of ABZ leads to poor oral absorption when administered orally.
• The lack of oral absorption has been linked to therapeutic failures following oral administration.
 Nanocrystals (NC) are defined as nanoparticles (typically 200–500 nm) composed of practically 100% drug.
• NC are generally produced as aqueous dispersions (nanosuspensions), which usually need further solvent
removal in order to obtain redispersible powders.
• NC display series of benefits in oral administration of poorly soluble drugs, including improved absorption,
higher bioavailability, rapid action onset, reduced fed/fasted state and intersubject variability.
 When ABZ is formulated as NC, a sharp increase in the specific surface is produced, which leads to increased
dissolution rate, saturation concentration and mucoadhesion.
 An improved PK performance of the nano-sized formulation was observed in mice; this could potentially enhance
the therapeutic response of certain parasitic diseases (i.e., hydatid cyst, ancylostomiasis) to ABZ.
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